VEGFA and hepatocellular carcinoma: Conversely, DUR/TRE represents a groundbreaking combination therapy that employs only immune checkpoint inhibitors (ICIs), constituting the first pharmacotherapeutic regimen for HCC that is devoid of VEGF-inhibitory effects.